F2 and pertussis: Mixed priming (wP/aP/aP) using the WHO-prequalified 5-in-1 wP vaccine (Pentabio, PT Bio Farma, Indonesia) and 3c-aP vaccine formulation containing PT, FHA, and PRN pertussis antigens (Infanrix hexa, GlaxoSmithKline, Australia) was noninferior to the homologous aP-only schedule (aP/aP/aP) with respect to anti-PT antibody titres at 6 and 7 months old.